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Abstract
The systemic renin-angiotensin system mainly regulates blood pressure and maintains 
kidney function. Recent studies have realized that renin-angiotensin system (RAS) has 
been found in many tissues, such as heart, liver, and kidney. Although RAS in heart 
and kidney has been well documented, the RAS in the liver has been evaluated in a few 
studies. Therefore, this chapter will be assessed it. Based on findings, RAS in the liver 
has presented almost all of its components, such as angiotensin-I (Ang-I), angiotensin-
II (Ang-II), angiotensin-converting enzyme (ACE), angiotensin type-1 receptor (AT1), 
angiotensin type-2 receptor (AT2), named as classical RAS. Expect these components, the 
local RAS has had alternative pathway components, including angiotensin-converting 
enzyme 2 (ACE2) and chymase. Classical RAS has an opposite effect of alternative RAS. 
Although these local RAS might not be such a crucial for the tissue, it could be a more 
vital function under pathophysiologic conditions. The chapter the local RAS in the liver 
the under both physiologic and pathophysiologic conditions is highlighted.
Keywords: angiotensin-II, angiotensin-converting enzyme 2, local renin-angiotensin 
system, liver pathologies
1. Introduction
Although early studies focused on the systemic renin-angiotensin system (RAS) which are 
important endocrine cascade to regulate the salt-water balance, scientists have recognized 
there is one more RAS, called as local or tissue RAS except for classical systemic effects [1]. 
The first recognition of local RAS has been reported that the in dog’s brain the renin was 
found [2]. Then, various tissues, such as the heart, liver, kidney, vasculature, skeletal muscles, 
pancreas, retina, adipose, neuronal, and reproductive tissue, have been shown to present local 
RAS [2–6]. Though systemic RAS can have a role in the regulation of cardiovascular homeo-
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stasis, there is accumulating evidence to suggest that the local RAS may affect tissue angio-
genesis, proliferation, cell growth, apoptosis, tissue inflammation, differentiation, hormonal 
secretion, fibrosis and/or dependent of systemic RAS. The local RAS has the paracrine effect 
in the tissue. Indeed, it does not have to come along with the systemic RAS [2, 5].
The liver is critical organ to maintain not only to glucose homeostasis [7] but also almost all 
of the body’s metabolic activities. The liver tissue has a great regeneration capacity against to 
repair of liver injury also [8]. The organ has reported existing both of systemic and local RAS 
[7]. The chapter could, therefore, focus on the local RAS in liver. However, there are limited 
studies available to study on local RAS. So, the aim of the present chapter is to analyze and 
sum up the participation of local RAS on both physiology and pathophysiology of liver tissue.
2. The renin angiotensin system in liver
2.1. The component of local renin-angiotensin system in liver tissue
The component of local renin-angiotensin system in liver is divided two as a classical and 
alternative component of liver renin-angiotensin system.
2.1.1. The classical component of local renin-angiotensin system in liver tissue
Before starting to evaluate the physiological and pathophysiological importance of RAS, it 
should be given some recent findings about which component of RAS present in the liver 
tissue. Giving that the elements of the system are so important to bring out its effects on the 
target tissue, it is expressed that almost all of RAS components could present in the liver tis-
sue, like other organ and tissue. One common consideration about RAS might be upregula-
tion and/or disruptions of distributions of its components, including angiotensinogen, renin, 
ACE, Ang-II, and AT1 (Figure 1) [6]. One of the recent data shows that local RAS components 
were found at cholangiocytes [2]. Hepatic Kupffer cells [3] and nuclear region of hepatocytes 
[4] also locally produce angiotensin-II (Ang-II) [9].
Angiotensinogen, predominantly produced in the liver, is one of α2-globulin glycoproteins 
with 452 amino acids around 60 kDA [2]. Although angiotensinogen is well known to produce 
in the liver, local angiotensin synthesized was also reported in a few hepatocytes from and 
Kupffer cell in human tissue [8]. Although it is clear that the primary source of the precursor 
of angiotensinogen is the hepatocytes, Kupffer cells, and bile duct epithelium have produced 
to low level of angiotensinogen as well. Cirrhotic livers are reported to increase angiotensino-
gen and plasma renin level and activity in both humans and animal studies [6]. Depletion of 
angiotensin is emphasized to lead to hypotension, and kidney pathomorphological changes, 
decrease survival. The authors suggested that liver and brain angiotensin are enough to main-
tain blood pressure and prevent pathomorphological changes in the kidneys [10]. This informa-
tion is emphasized that angiotensin produced from the liver is the primary source of the body.
Even though Ang-I production via renin has not been found in the liver tissue, some clues are 
indicated that de novo production of it might be found locally in hepatic-mesenteric vascular 
beds and circulation plasma as well [6].
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Renin is expressed at the liver as well [5–7]. It is surprising that renin expression in the female 
is higher than male in liver tissue of both mice and rats [7]. Furthermore, its expression was 
found at liver cells such as cholangiocytes, hepatocytes, and hepatic stellate cells (HSC) [9]. 
Renin receptor was reported to have low-level expression mRNA at liver and kidney, but the 
high level of the heart, brain, and placenta. Also, it was outlined that the animals have been 
reported to suffer from liver fibrosis, nephroangiosclerosis probably leads to the activation of 
ERK1/2 and enhancing of plasminogen activator inhibitor-1, cardiac, and aortic hypertrophy 
when prorenin transgene express at liver in the rats [11].
The expressions of ACE and AT1 are found at vascular endothelium, hepatocytes, and bile 
duct epithelial cells. This distribution could be changed under pathologic conditions. For 
example, in the fibrotic liver, fibrous septa, mesenchymal cells (HSCs and myofibroblasts), 
and Kupffer cells are also produced to ACE and AT1 [12]. AT1 is predominantly found in the 
liver. However, AT2 genes are found in a trace amount or not in the normal and pathologic 
liver as well. At the same time, it was reported so far that AT2 receptor gene expression was 
found from isolated human hepatocytes and stellate cells. This high expression of AT1 might 
be the elevation of the liver due to the participation of it in the inflammatory, proliferative 
process, and vascular effect in the liver. This info consists of fibrosis and the degree of portal 
hypertension to the AT1 expression on septal myofibroblast [6]. The receptor is pointed out to 
Figure 1. A schematic diagram of the classical and alternative renin-angiotensin system. ACE: angiotensin converting 
enzyme, ACE2: angiotensin-converting enzyme-2, Ang-I: angiotensin-II, Ang-II: angiotensin-II, Ang-1-7: angiotensin1-7, 
Ang-1-9: angiotensin1-9, AT1: angiotensin type-1receptor, AT2: angiotensin type-2 receptor, Mas: mas receptor. The 
figure was modified from Refs. [17, 18].
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be at hepatocytes, HSCs, Kupffer cells, bile duct cells, myofibroblast, and vascular endothelial 
cells [12]. One of the previous studies is stated that ACE could present only liver at tissue-
specific ACE knockdown animals, but not a gastrointestinal tract, heart, vascular or spleen. 
The only kidney might be seen ACE activity but at a trace level. Additionally hepatocytes, the 
testis is also found express of ACE at liver-specific ACE knockdown mice. Although there is 
no ACE found at vascular, blood pressure at liver-specific ACE knockdown mice is reported 
to be pretty standard. The authors implied that adequate ACE in the liver controls the essen-
tial kidney function for maintaining homeostasis, but there is no obligation to present of vas-
cular ACE expression to regulate normal blood pressure. Indeed, adequate ACE in any organ 
is enough to maintain kidney function, resulting in mean blood pressure control [13].
Ang-II might be present in cholangiocytes and activated HSC which is also highly express 
active renin, ACE at in vitro and in vivo studies [14]. Some recent studies have been shown that 
AT1 could present in the liver [5]. Ang-II production from cholangiocytes probably increases 
at bile duct ligation (BDL). The expression of RAS component at different liver cell types 
might have both paracrine and autocrine impact on the target tissue. It seems that activation 
of cholangiocytes RAS could trigger the other cell type’s RAS. This concept may help us to 
explain how to relate RAS at liver pathologies [14]. Many RAS components, such as renin, 
ACE, Ang-II, AT1, and ACE2 seem to be un-regulated under pathophysiological conditions 
[7]. But, Ang-II that can exist in the liver tissue could enhance at the pathophysiologic circum-
stance [6]. Ang-II relates to promoting some liver disease, i.e., liver fibrosis, and proliferation 
and activation of hepatic stellate cells. So, there is reported to have some prophylactic effects 
against to liver failure [7]. One of the previous studies noticed that active RAS blocking by 
either angiotensin-converting enzyme (ACE) or AT1 inhibition led to attenuate liver fibro-
sis by suppressing HCS and hepatic TGF-β1 in chronic liver injury [9]. The component of 
local RAS was found in the liver of obese and type-2 diabetes patients. The upregulation 
of angiotensinogen in liver was shown in type-2 diabetic patient with and without obesity. 
Its upregulation expression was also determined at hyperglycemia in obese Sprague-Dawley 
rats, but not in nondiabetic and diet-induce obese rats. Therefore, it is likely to diabetes than 
obesity much more related to hepatic angiotensinogen production. There is an active inter-
action determined between TNF-α and local RAS in liver. So, TNF-α increases ACE, angio-
tensinogen, and the expression of angiotensin AT1 mRNA in the liver. At this moment, the 
upregulation of local RAS may in the liver is associated with obesity and developing insulin 
resistance and liver fibrosis [14].
Recent studies have shown to the paradigm shift of RAS. Ang-II receptors and some proteins 
have been proved to interact with each other by using several methods. For example, it has been 
indicated that AT1-related protein probably acts a negative regulator, including its cell prolif-
eration and vascular remodeling by enhancing AT1 internalization. Angiotensin type-2 recep-
tor (AT2)-related protein has an adverse impact on the AT2 effect, e.g., growth. Furthermore, 
AT1 might form either homodimers or heterodimers with other partners, including AT2, bra-
dykinin B2 receptor, epidermal growth factor (EGF) receptor, dopamine receptor, endothelin 
receptor type B and Mas receptor. This dimerization of Ang-II receptors is unknown neither 
physiologic nor pathophysiologic importance. Therefore, more new studies are needed to get 
a better understanding of the dimerization function under physiologic and pathophysiologic 
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conditions [15]. Also, there is indicated to be the active interaction between RAS components 
in the mammals. The interaction was shown when renin or Ang-II infusion at perfused mam-
malian liver enhances angiotensinogen release, and this effect does not link the glucocorticoid 
secretion. But glucocorticoid present is required to maintain angiotensinogen gene synthesis. 
It should not rule out that such a kind of studies were carried out by using at the supraphysi-
ologic level of Ang-II. But, it also pointed out this positive interaction could be a more patho-
physiologic circumstance, such as depletion of sodium and water and hemorrhage, too [16].
2.1.2. The alternative component of local renin-angiotensin system in liver tissue
Alternative pathway has been thought for a while (Figure 1). The alternative paths are ACE2 
and chymase that are discuss in this chapter. ACE2 is found at heart, kidney, gastrointestinal 
tract as well as liver and lung. ACE2 is one of the type-I integral proteins, expressed funda-
mentally at the cell surface as an ectoenzyme. ACE2 has ectodomain at the membrane; how-
ever, metalloprotease ADAM17 is reported to modify to make an active soluble form of it. So, 
its soluble form could be detected in plasma and urine as well. Moreover, ACE2 is one of the 
members of the M2 zinc metalloproteinase family as well as somatic and testicular types of 
ACE. ACE2 has 805 amino acid residues and similarities with human ACE at 41%. Although 
somatic ACE has two active sites at N- and C-domains, ACE2 has only one active site. The 
other difference of ACE2 from ACE is a carboxypeptidase, but ACE is a peptidyl dipeptide. 
Moreover, ACE2 is reported not to blockage by using any ACEI, e.g., captopril, enalaprilat 
or lisinopril. ACE2 can cleave only one residue from C-terminus of Ang-I and Ang-II that 
have limited biological effects. The ACE2 effects on Ang-I and Ang-II could produce angio-
tensin-1-7 (Ang-1-7) and angiotensin-1-9 (Ang-1-9), respectively. But, in these two pathways 
Ang-1-7 is produced more likely by ACE2. That is why ACE2 could accept to provide Ang-
1-7. Ang-1-7 interacts with AT2, BK2 and Mas receptors. Taking together this finding, ACE2-
Ang-1-7-Mas axis could modulate the axis of ACE-Ang-II-AT1 [6]. Based on these findings, it 
is reported that Mas-binding Ang-1-7 produced by ACE2 is the fifth receptor of RAS. ACE2 
was increased in liver injury and cirrhosis, resulting in enhancing Ang-1-7 at the plasma and 
tissue level. The local RAS elements are introduced to express from the cancerous tissue. 
Some evidence has been shown that RAS is related liver cancer. For example, ACE and AT1 
antagonist drugs (captopril, irbesartan; respectively) give rise to minimize cancer growth, 
liver metastases and angiogenesis in colorectal cancer liver metastases animals [5]. It was 
shown that ACE, Ang-II and AT1, classic components of RAS, were high expression in rats 
with biliary fibrosis as well as ACE2 in liver, and plasma, Mas in liver, Ang-1-7 in plasma. This 
finding can be concluded that local RAS in the liver has both classical (ACE-Ang-II-AT1) and 
ACE2-Ang-1-7-Mas pathways that play important role in chronic injury. RAS pharmacologi-
cally inhibition by ACE and AT1 inhibitors is well established to have a therapeutic effect on 
many diseases including hypertension, heart failure or diabetes due to blocking Ang-II and 
AT1. Some recent evidence has been pointing out that these inhibitions have caused to elevate 
ACE2 and Ang-1-7. The most impressive result from these kinds of experiments is that there 
is no functional effect of ACE2 elevation in normal animals. Therefore, ACE2 elevation could 
conclude to be pivotal importance under the only pathophysiologic circumstance, but not a 
physiologic condition [6].
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The other alternative Ang-II production process is via chymase. The enzyme, chymase, is 
a chymotrypsin-like, presents in the mast cell secretory granules. It is also produced as an 
inactive form and activated by dipeptidyl peptidase I (DPPI), a thiol proteinase, in the mast 
cell granules. The optimal pH for DPPI is at 6.0. But mast secretory granules have controlled 
at 5.5, and there is no chymase activity at 5.5. The optimal pH for chymase is around 7 and 
9. As soon as the chymase is secreted into interstitial tissue at 7.4, it can reach to its optimal 
pH, resulting in gaining activation. The only mast cell-stimulated tissue can secrete it under 
inflammation circumstance because there may be found any chymase inhibitors in the regular 
target. Chymase can produce Ang-II from Ang-I. Additionally, chymase can activate TGF-β 
and metalloproteinase-9 (MMP-9) from their inactive forms. Both of them participate in tis-
sue fibrosis and inflammation. It is stated that there might be a positive correlation between 
Ang-II and chymase in the human liver fibrosis due to finding a high level of both. Moreover, 
it is suggested that chymase and Ang-II levels could indicate fibrotic severity. So, chymase 
inhibition could alleviate the liver fibrosis in animal models. Therefore, new studies are 
required to clarify the interaction of chymase, Ang-II, and liver fibrosis [19].
2.2. Intracellular pathway of local renin-angiotensin system in liver
Ang-II is reported to cooperate with an intracellular signal pathway to amplify its effect. 
Therefore, in this section some recent information about the intracellular mediators of local 
RAS is given. One of these signal amplification pathways may be mitogen-activated protein 
kinases (MAPK), which are ERK1/2, JNK, and P38 MAPK. MAPK plays a crucial role in cel-
lular differentiation, proliferation, migration, and fibrosis. ERK1/2 has some vital effects on 
cholangiocyte proliferation. Additionally, MAPK, Ang-II can activate nuclear factor-κB (NF-
κB) [20]. Ang-II gives rise to trigger proliferation by stimulation of the cAMP signal pathway 
[9] as well. It is noticed that human fibrotic liver samples were found less AT1 expressing 
at hepatocytes, but high expressing in hepatic stellate cells (HSCs), vascular endothelium, 
and bile duct epithelium. The local RAS-induced HSC via AT1 and activation of NADPH 
oxidase results in fibrotic liver, and cholangiocyte proliferation by AT1 triggering a cAMP, 
PKA, ERK1/2, and pCREB-dependent signaling pathway [9]. Hepatic stellate cell (HSC) is the 
most effective cell type of liver to the deposit of connective tissue at respond of liver injury. 
Fifteen percentage of liver tissue composes of HSC. Both of Ang-II and renin are reported to 
increase liver cirrhosis patients. It is reported that Ang-II might relate to the development of 
the liver fibrosis by activation of HSC via TGF-β1 through AT1. This exacerbating effect of 
Ang-II on liver fibrosis probably mediates phosphorylation of c-Jun and p42/44 MAPK in 
AT1. Activated HCS produces Ang-II that led to fibrosis via NADPH oxidase. Also, a definite 
link is found between TGF-β1 and Ang-II for the development of liver fibrosis. Therefore, 
Ang-II may give rise to elevated TGF-β1, resulting in the production of collogen-1 via AT1 in 
the liver. There is a kind of positive feedback in the liver which is that TGF-β1 activates HSC, 
and HSC can produce much more TGF-β1 production [21].
Most of these injury factors are linked to oxidative stress based on reactive oxygen (ROS) and 
reactive nitrogen species. The ROS production is produced by some enzymes, for instance, 
mitochondrial leakage, tetrahydrobiopterin coenzyme oxidation, xanthine oxidase, endo-
thelial nitric oxide synthase, nicotine adenine dinucleotide phosphate (NADPH) at both 
Renin-Angiotensin System - Past, Present and Future220
membrane and cytosolic compartment [2]. It might seem that oxidative stress is also critical 
pathways for RAS’s effect, especially in development of pathologies [22]. HSC could also 
relate to oxidative stress by increasing AT1 and nonphagocytic NADPH oxidase enzyme sys-
tem. NADPH oxidase is one of multicomponent enzyme systems, which is activated by rac1, 
p47phox, gp91phox, p22phox, nox1, p40phox, and p67phox. Ang-II triggers p47phox phos-
phorylation via AT1 on activated HSC to increase ROS production. One of the AT1 receptor 
antagonists, losartan, could block the ROS formation through NADPH oxidase inhibition [23]. 
This formed superoxide by NADPH oxidase could oxidize tetrahydrobiopterin (BH4) that is 
a cofactor of nitric oxide synthase (NOS). So, if BH4 is formed at high concentration, NOS 
enzyme could be dimerized and produces nitric oxide (NO). But, when the BH4 level is low, 
the balance between NOS and BH4 can shift to produce superoxide, resulting in decreasing 
NO production but increasing peroxynitrite (ONOO) formation. So, AT1-initiated oxidative 
stress could lead to inactivate NO, lipid oxidation, and activate redox-sensitive genes, e.g., 
proinflammatory cytokines, matrix metalloproteinases, chemotaxis, and adhesion molecules 
[15]. So, local RAS can produce ROS via Ang-II-AT1 axis [2].
Ang-II might relate to inducing tumor progress interaction with HSC in liver. Ang-II activates 
cAMP but not IP3. But many studies have shown that AT1 activates IP3, diacylglycerol, and 
reactive oxygen species. The activation of cAMP by Ang-II was also shown in renal mesangial 
cells. Moreover, PKA/ERK/CREB signaling pathway is reported to be an important intracel-
lular component of the Ang-II effect on stimulated biliary proliferation. This notion was sup-
ported by attenuation of proliferation through inhibition PKA and ERK1/2. This intracellular 
pathway was present cholangiocytes that have shown own local RAS. Ang-II causes fibrosis 
by expresses of collagen 1A1 and fibronectin 1 in a primary rat cholangiocyte cell line, as well 
as IL6, which is one of the proliferative cytokines playing a role in biliary hyperplasia [9].
The other pathway might be Jak2/STAT for local RAS in the liver. Jak2 kinases are vital 
for the transcription of angiotensinogen mRNA in vivo. Ang-II stimulates STAT5B and co-
activator of it, p300, in the liver. It is also stated that STAT3/p300/CBP pathway is critical 
for IL6 dependent activation of human angiotensinogen gene in HepG2 cells. NF-κB might 
involve Ang-II’s inflammatory response, as well as IL-6, inducing the hepatic acute-phase 
reaction [24].
Ang-II has played an important role in the development of fibrosis, including liver, heart, 
lung, and pancreas. Some soluble factors such as cytokines, oxidative stress, chemokines, and 
growth factor increase ECM production [25]. TGF-β1 is one of the most profibrotic cytokines 
to accumulate some extracellular matrix (ECM) [15]. Local Ang-II predominantly induces of 
TGF-β [25]. Some of ECM element is noncollagenous glycoproteins, including hyaluronic acid 
(HA) and proteoglycan. Therefore, elevation of HA in plasma is given an important clue to 
assess the diagnosis of liver fibrosis. Ang-II is locally synthesized by activated HSC, more-
over, and crucially involves the development of liver fibrosis. α-SMA is considered to be an 
important indicator for activation of HSC. It is reported that the positive effect of Ang-II is not 
only to activate and/or proliferate of HSC but also elevate fibrogenic cytokine, collagen depo-
sition, and matrix synthesis. When RAS can block by using inhibitors for AT1 or ACE, Ang-
II’s fibrotic effects decrease. Local RAS plays a crucial role in the development of liver fibrosis 
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[15]. How local Ang-II can help established the fibrosis may be related to transforming growth 
factor-beta (TGF-β). More attention would give for the interaction of Ang-II and TGF-β. There 
are many TGF-β isoforms; however, TGF-β1 is the most investigated isoform. TGF-β associ-
ates the intracellular Smad signaling. Therefore, the TGF-β/Smad signaling is reported to play 
a crucial role to accumulate collagen, one of the major component proteins of the extracellular 
matrix (ECM), resulting in tissue fibrogenesis. Smad acts the most important transcriptional 
factor for TGF-β-mediated responses including fibrosis. Ang-II has been indicated to induce 
Smad2 and Smad4 signaling via AT1 for gene transcription, but the transcription is not strictly 
bound to TGF-β. Also, Smad7 has a function to counteract of the TGF-β pathway. Moreover, 
when Smad3 is decreased, or Smad7 expression is increased, tissue fibrosis from liver, skin, 
or kidney is indicated to diminish. Downregulation of CTGF is also prevented from develop-
ing fibrosis. CTGF is one of the crucial elements of fibrosis at a couple of organs. CTFG is a 
potent trigger of myofibroblasts and ECM synthesis and deposition. So, CTFG is upregulated 
by Ang-II by AT1, resulting in activation of Smad signaling and independent Rho/Rho kinase 
pathways of TGF-β. Based on these findings, both ACE and AT1 antagonists could alleviate 
CTGF expression and fibrosis as well. Also, the reverse can do the same effect on fibrosis [25]. 
Not only does TGF-β decrease the degradation of the matrix by metalloproteinase (MMP) 
but also synthesize connective tissue growth factor (CTGF), which is autoinduction of TGF-β. 
That is why Ang-II blockage by ACE or its receptor inhibition could reversed the tissue fibro-
genesis in target tissue by modulation of TGF-β1 expression. Fibrosis is one of chronic and 
progressive processes mediated by the complex interaction between cell, ECM, cytokine, and 
growth factor. However, there is still no efficient and well-tolerated antifibrotic therapy due 
to lack of the main molecular pathways of it. The inhibition of Ang-II is reported to attenuate 
40–60% TGF-β1 production, resulting in a reduction of hepatic fibrosis. Ang-II can stimulate 
Smad pathway also activate CTGF by TGF-β independently. The interaction of local Ang-II 
and TGF-β1 should, therefore, be elucidated in previous studies [25].
2.3. The function of local renin-angiotensin systems in the liver tissue
Locally formed angiotensin peptides have aggravated system’s effects, notably cell growth, 
antiproliferation, apoptosis, production of reactive oxygen species (ROS), secretion of the 
hormone, proinflammatory and profibrogenesis. Till date, the importance of hepatic RAS 
under both physiologic and pathophysiologic condition has not been evaluated well yet, 
expect for heart and kidney [6]. However, the local RAS becomes so important to under 
pathophysiologic conditions in hepatic tissue based on the little present of RAS members 
compared to systemic RAS [12]. The local RAS plays a paracrine role in modulation of some 
processes, including inflammation, fibrosis, angiogenesis, cell proliferation, apoptosis, and 
survival under both physiological and pathophysiological circumstances. After recognition 
of an alternative RAS pathway (ACE2, Ang-1-7, etc.), it has to be changed to view its impor-
tance of tissue function. The task can be divided as its action on the systemic level including 
blood pressure control, tissue perfusion, and sodium and fluid balance, and on paracrine 
level including proliferation, inflammation, angiogenesis, apoptosis [17]. Consequently, 
local RAS might be amply of some diseases at liver since angiotensin-II gives rise to trigger 
oxidative stress. Moreover, the liver has an important role to detox of toxin which means that 
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it may be very susceptibility to oxidative stress [22]. Recent data, from animal and human 
studies, suggest that the counteraction of local RAS would be of importance in modulating 
of liver diseases. The RAS not only can regulate blood pressure and volume, but also modu-
lates inflammatory process [20]. The local RAS has importance under both physiologic and 
pathophysiologic conditions [6].
Local RAS plays a pivotal role for the tissue function both physiologic and pathophysiologic 
conditions based on paracrine and autocrine impacts of it [26]. RAS also modulate the body 
metabolic process [18]. Locally produced RAS has some specific role in apoptosis, angiogen-
esis and regulation of cell proliferation [27]. The RAS is thought to participate probably in 
liver regeneration and tumor as well [27]. Ang-II is important because of its effects including 
vasodilatation, antiproliferation, elevation of baroreflex sensitivity, facilitation of bradykinin 
activity at bradykinin receptor (BK2), inhibition of C-domain ACE activity and AT1 receptor 
antagonism, but some of them are counteract with Ang-II effects [6]. It is necessary to find the 
answer of the question why the local RAS has crucial regulation of tissues. One of the explana-
tions of the issue is that the amount of local RAS components is independently controlled by 
its level in tissue [28]. It means that the mimetic or antagonist drugs could not be able to alter 
of the RAS members’ concentration. The other possible explanation of it is that local Ang-II 
has a vital role in controlling of sympathetic neurotransmission and smooth muscle hyper-
plasia without effects of sodium balance which is under controlled by systemic Ang-II [28].
RAS was probably reported to be related to some hepatic pathogenesis, including hepatic 
stellate cell inflammation, proliferation, elevation of portal vein pressure, and hepatic fibro-
genesis, as well [29]. RAS activation was reported in the patients with liver cirrhosis [30, 31], 
liver inflammation [12], nonalcoholic fatty liver disease [12], and fibrosis [4, 9]. RAS triggers 
oxidative stress at liver [32]. Moreover, blockage of RAS in the liver has improved for regen-
eration and inhibition of tumor progression [17]. There is an active interaction between the 
plasma ACE level and patient with liver fibrosis [29]. On the other hand, the local production 
of Ang-II might not be entirely blocked by ACE inhibitors due to that there are alternative 
pathways that are chymase [33].
Angiotensin-II, the most active member of RAS, has been indicated to have some pathologic 
effects, such as inflammation, oxidative stress, prothrombotic [18], cirrhosis [34], and acute 
liver injury [35]. Ang-II causes to contract vascular smooth cell and triggers nicotinamide ade-
nine dinucleotide phosphate oxidase (NADPH), thereby elevation of superoxide radicals [20]. 
Interestingly, local RAS in liver and tumor necrosis factor-alpha (TNF-α) was suggested to 
have some interaction for developing insulin resistance and atherosclerosis by activation of 
plasminogen activator inhibitor-1 (PAI-1) production [14]. By better knowledge of inhibition, 
local RAS in the liver might be able to prevent at least of these kinds of diseases. Local RAS has 
a pivotal role under the pathophysiologic circumstance, resulting from tissue inflammation, 
trauma, hypoxia-ischemia, ischemia-reperfusion, hyperglycemia, hyperlipidemia, hyperho-
mocysteinemia, and hyperuricemia and autocrine/paracrine effect on the target organ [2]. One 
of the recent studies reported that RAS blockage by using ACE, captopril, inhibits the liver 
tumor growth in mice. Moreover, captopril was indicated to increase liver regeneration as 
well. How the captopril could enhance its recovery might be explained by increasing of HCS. 
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HCS can secrete MMP-9, resulting in accumulation of extracellular matrix. HCS could produce 
some terminating factors including IL-1, TGF-β at the late stages of liver regeneration [27].
In addition to other effects, Ang-II could modulate the immune system by releasing macro-
phage/monocyte chemoattractant protein (MCP)-1, MCP-2, granulocyte colony-stimulating 
factor as well as increasing macrophage infiltration. It might be thought that macrophage 
infiltration can fight microorganism and tumor cells. The macrophage’s role in the late stage 
of tumor development is still needed to clarify. But some evidence is shown that macrophage 
infiltration might trigger cancer growth and metastasis. For instance, Kupffer cells could pro-
mote immune escape and facilitate metastatic colonies at a late stage of the disease. The macro-
phages could produce many cytokines to initiate angiogenesis, tumor growth, and metastasis. 
It is reported that Ang-II could stimulate macrophage infiltration and angiogenesis through 
AT1 and VEGF in a melanoma model. There might be an active interaction between macro-
phage and Ang-II. Because macrophage could produce ACE for the synthesis of Ang-II [5]. 
Ang-II increases the production of TNF, IL-1β the infiltration of CD43+ inflammatory cells 
which are inflammatory proteins [36].
2.4. The crosstalk of local renin-angiotensin system and liver pathologies
This chapter’s main aim is underlined of local RAS and its contribution of liver pathologies. 
But, it should be accepted that there is a limited study to evaluate or investigate this interac-
tion. Analyzing the interaction might be difficult. Because local and systemic RAS are hard 
to distinguish from each other. Also, they both could involve in developing liver pathologies 
or changing of liver function for some cases. That is why it will be divided the subhead of 
each liver pathology.
There are many factors determined to cause to liver diseases, such as alcohol, viral hepatitis, 
drug abuse, and autoimmune hepatitis. Chronic damage to liver causes liver fibrosis, leading 
to liver cirrhosis. Liver fibrosis is also produced by type-2 diabetes, concerned with obesity 
and steatosis that is fat accumulating in the liver [18]. There are two main cell types to over-
come that kind of pathologies, as well as healthy maintaining the liver function. One of these 
cells is Kupffer cells. The cells are a type of mobile macrophages bound to endothelial cells. 
The cells physiologically synthesize immune-suppressive cytokine such as IL-10 to block HSC 
activation and/or collagen production. When the liver is injured, Kupffer cells are activated 
and start to release inflammatory cytokines, associating with apoptosis. But, the others such 
as IL6 or IL-1ß could involve liver fibrosis by increasing ECM, collagen-I, some fibrogenic 
cytokines such as TGF-ß1. The second type of cells is hepatic stellate (HSC), perivascular 
mesenchymal cells that are located in Disse space at the liver. The task of HCS is to metabo-
lize vitamin-A, synthesize cytokines, growth, and inflammatory factors. That is why the cell 
plays a vital role in development of liver fibrosis and also participate liver inflammation [18]. 
High activation of ACE and angiotensin-II type-1 (AT1) receptor suggests at the liver disease. 
Furthermore, AT1 at liver plays a role in HSC activation by phosphorylation of Janus kinase-2 
[37]. Besides, AT1 knockout mice were shown to decrease hepatic fibrosis. Also, Ang-II stim-
ulates to the hepatic stellate cell for production more Ang-II [32]. When Kupffer cells are 
triggered by oxidative stress to produce proinflammatory cytokine after liver degenerations, 
resulting in also activation of HSC subsequently to synthesize collagen. After activation of 
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HSC, the cells moves to the degenerative area, then transform into interstitial myofibroblast. 
The myofibroblast can also produce cytokines, chemokines, matrix metalloproteinases, and 
tissue inhibitors of metalloproteinase (TIMPs). Local Ang-II has also affected on endothelial 
function. The endothelial cells have many tasks for regulation vascular tone, coagulation, cell 
growth, and leukocytes migration. All of the function of the endothelial cell requires a balance 
between vasodilatation such as nitric oxide and vasoconstriction such as Ang-II. Endothelial 
cell is very sensitive to the cell redox state [18].
2.4.1. The local renin-angiotensin system in liver and portal hypertension
Portal hypertension is one of the complications of cirrhosis having high of morbidity and 
mortality rates. Portal hypertension is interacted with RAS and sympathetic system, result-
ing in retention of water and salt then ascites [38]. If portal hypertension could be decreased, 
the complications of it could be declined as well. One of the drugs causing to reduce portal 
pressure is RAS inhibitors. Based on the suggestion, cirrhosis might cause vasodilation at 
the systemic and splanchnic vessel, so RAS could be activated to make up for the hypo-
tension, resulting from Ang-II production. Elevated Ang-II gives rise to high-intrahepatic 
resistance both static and dynamic ways, and portal venous inflow through sodium and 
water retention. Ang-II also increases aldosterone production which has been thought to 
participate in developing inflammation, oxidative stress, endothelial dysfunction, insulin 
resistance, and fibrosis. But, there is still more evaluation for analyzing of the beneficial 
effect of RAS inhibitions on the patient with portal hypertension-induced by cirrhosis. Not 
only does Ang-II cause vasoconstriction in the hepatic microvasculature, but also endo-
thelin, thromboxane-A2, leukotrienes, and norepinephrine also cause the vasocontraction. 
Therefore, it might be suggested that nitric oxide (NO) could not have efficient enough to 
overcome of that vasoconstriction. NO impairment could, therefore, help to progressive of 
liver dysfunction. So, the blockage of RAS may have a therapeutic effect on the early stage of 
cirrhosis. The local RAS might have some contributions to developing portal hypertension 
and virtually cirrhosis [39].
2.4.2. The local renin-angiotensin system in liver and hepatocellular carcinoma
Hepatocellular carcinoma (HCC) has been reported to be the most prevalent type of cancer 
throughout worldwide [30], being the fifth most predominant tumor case [17]. The patient with 
HCC has been informed to have only 5 years survival due to metastasis and recurrence based on 
angiogenesis [30]. HCC is one of the most severe complications of cirrhosis [6]. Although liver 
is one of the few tissues having regeneration, liver resection can perform at HCC and colorectal 
cancer (CRC) liver metastases patients for removing tumorous part of tissue [17]. CRC is the 
second leading cause of death at both genders, most of which are related to liver metastasis by 
70% of CRC patients [17]. Liver resection is maybe best treatment for these diseases [17]. Also, 
some patients are indicated to die after liver resection operation due to metastasis of liver from 
the inside or outside tissue. This tumor recurrence is suggested based on some factor elevation 
including growth, angiogenic factor, and also modulation of extracellular matrix [17].
It is speculated that RAS might participate in liver regeneration and tumor modification 
by tumor proliferation and apoptosis, angiogenesis, and ECM remodeling [17]. RAS might 
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participate in the development of this carcinoma due to its angiogenic and prolifera-
tive effects. Moreover, Ang-II could enhance vascular endothelial growth factor (VEGF), 
the most efficient angiogenic factor, which is decline by ACEI in mice with tumor [6]. 
Therefore, studies are indicated to be interaction Ang-II and vessel cancer growth. ACE 
having a homolog of ACE can convert to Ang-1-9 and Ang-1-7 from Ang-I and Ang-II, 
respectively. Elevated ACE2 is reported to block cell invasion, angiogenesis, VEGF in non-
small cell cancer cell line. The activation of VEGF by Ang-II is thought to be concerned 
with VEGF/eNOS pathway and inflammation as well. So, it is well documented that RAS 
plays a role in cancer progression or metastasis. Moreover, the alternation of RAS element 
in the local cancer tissue might be related to cancer severity. RAS could be elevated in the 
patient with cirrhosis, found a high level of both Ang-II and Ang-1-7. Ang-1-7 is a potent 
antifibrosis. Ang-II can trigger VEGF in dose and time-dependent manner, also HSC for 
contraction and proliferation. One of the studies was shown that AT1 inhibition markedly 
declines liver fibrosis and VEGF expression. So, they pointed out that the interaction of 
Ang-II-VEGF is so important for the development of liver fibrosis and HCS activation. 
HCC patients were shown to have low expression of ACE2, although Ang-II, ang-1-7 and 
VEGF were high levels in the patient [30].
In addition to VEGF, Ang-II’s angiogenic effect might be concerned with epidermal growth 
factor, angiopoietin 2, basic fibroblast growth factor, and an insulin-like growth factor that 
plays a major role in both liver regeneration and tumor growth. Moreover, both systems 
are reported to associate with liver regeneration. Although ACE-Ang-II-AT1 axis might be 
enhanced at early stages of its restoration, ACE2-Ang-1-7-Mas axis could be activated at the 
later stages of the recovery. RAS expression was reported to be cancer specific alternation. 
For examples, CRC metastases were indicated to elevate AT2, ACE, and Mas expressions, 
but decrease AT1 and angiotensinogen expressions. Moreover, AT1 was speculated to be 
healthy tissue cells, including Kupffer as well as the tumor and stromal infiltrating cell. 
But, the other RAS receptors, e.g., Mas, were found an only tumorous liver tissue. The other 
example was indicated that ACE localization was suggested to be hepatic endothelial cells, 
apical and cytoplasm of cancer and vascular cell because of neovascularization and cancer 
cell homeostasis. Also the other CRC metastases from colorectal adenoma, sarcomas pros-
tate cancer was also speculated to be the crucial importance of RAS. So, pharmacological 
blockage of RAS by ACE or AT1 antagonist gives rise to decline the growth of cancer. ACE 
antagonist was probably decreased the severity of tumors in some kinds of tumor, e.g., 
prostate, breast, and CRC. The other view was pointed out that cancer growth could be a 
decline in AT1 knockdown mice based on attenuation of VEGF, angiogenesis. This find-
ing was suggested that AT1 plays an important role. Also, the drop of AT1 might cause to 
enhance alternative RAS pathway action (ACE2, Mas). The other explanation of these was 
that when AT1 was chronically blockaded by the drug, it might be shifted a balance to AT2 
which is well known to have a different effect from AT1. Although AT1 has mitogenic and 
angiogenic effects, AT2 triggers apoptosis and inhibits proliferation. AT2’s effect on VEGF is 
the double direction. AT2 is reported to activate VEGF; it is also shown to antagonize VEGF 
as well. The other aspect should also be considered that AT2 could modulate NO and BK 
pathways in which both has participated angiogenesis. Moreover, the other candidate for 
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angiogenesis process could be proliferator-activated receptor-γ (PPAR-γ) because plenty of 
AT1 antagonists enhanced PPAR-γ attenuation of cancer proliferation. Why many of studies 
have focused on the regulation of angiogenesis by RAS is related to how to regulate tumor 
growth. But it should be noticed that Ang-II could be produced by another enzyme, chy-
mase which also enhance Ang-1-7. Thus, ACE inhibitors can just block one way, resulting 
in one alternative pathway still efficient for its production. The other important point is that 
the alternative RAS pathway could syntheses Ang-1-7as well. Ang-1-7 has been reported to 
reduce metastases in mice since it led to diminish in cyclooxygenase-2. Elevation of cyclo-
oxygenase-2 is related to cancer growth, inflammation, angiogenesis, thanks to enhancing 
prostaglandin E2, D2, and thromboxane A2. Ang-1-7 could also moderate thromboxane A2 
as well as prostaglandins. ACE inhibition increases not only Ang-1-7 levels but also BK lev-
els. However, the elevation of BK is not beneficial effect on the tumorous cell due to stimula-
tion of cancer growth by angiogenesis and inflammation [17].
2.4.3. The local renin-angiotensin system in liver and cholangiocarcinoma
Cholangiocarcinoma (CCA) is one of the uncommon malignant tumors. This tumor type 
is also related to local RAS. According to a recent study, the development of CCA is asso-
ciated with inflammation and biliary duct cell injury due to obstruction of bile flow rate. 
Cytokines productions in the biliary tissue by inflammation process are responsible for 
the malignant transformation. Locally produced Ang-II is reported to involve to the prolif-
eration and activation of CCA cells which express Ang-I as a growth factor in local effect 
(autocrine and paracrine). The local effect of Ang-II could modulate the balance between 
intrahepatic proliferation and fibrosis. Moreover, the patient with CCA was found to high 
ACE level. That is why it will be vital to understand the interaction of CCA and RAS in 
developing new strategies for cancer therapy to improve the patient’s life and life quality 
as well [40].
2.4.4. The local renin-angiotensin system in liver and cancer growth
Cancer growth and metastasis are well documented to related angiogenesis. The new vessel 
growth is associated with Ang-II and VEGF/VEGF-A, especially useful in vascular endo-
thelial cells. Ang-II’s new vessel formative effect is through AT1. Its angiogenic effect of 
Ang-II is consisted within several cancer models. For instance, VEGF is shown to secrete 
through Ang-II-AT1 in ovarian cancer cells. Also, ACE inhibitors are reported to decline the 
neovasculature in cancer tissue. VEGF is defined to use similar pathways in many tissues. 
After VEGF overexpression in cancerous tissue, the fibrin at extravascular is accumulated, 
but the extracellular matrix is degraded. Then, the endothelial cell can migrate into the 
stroma, forming enlarged but thinned vessel-walled, named as mother vessel. After this 
stage, the vascular development is reported to differ from each tissue and many daughter 
vessels from mother vessel could be developed branches and caused to disrupt vessel orga-
nization, including muscular arteries and veins and produced glomeruli bodies, a kind of 
disorganized tangle vessel (Figure 2). Ang-II is indicated to enhance vascular permeability 
by increasing some permeability factors such as prostaglandins, nitric oxide, NF-κB, VEGF, 
and endothelin [5].
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2.4.5. The local renin-angiotensin system in liver and cholangiopathy
Primary sclerosing cholangitis (PCS), an ischemic cholangiopathy, might be related to local 
RAS within the portal tract. Ang-II production may increase in portal tract due to biliary 
epithelial stimuli, including infections, drugs, and toxins. The other possibility of activa-
tion of RAS in it-portal tract relies on localized biliary tract ischemia such as microvascular 
Figure 2. The development of cancer angiogenesis, growth and metastasis [5].
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thrombosis; immune-mediated endothelial is or toxic injury to arterioles. Local RAS in the 
liver has suggested that Ang-II could modify bile secretion by elevation of the production 
of bile acid independent bile flow and by the nonvascular effect of Ang-II on hepatocytes 
or biliary epithelial. Elevation of Ang-II production can trigger some responses, such as 
inflammatory cytokines releasing from mesenchymal cells, biliary epithelia, and vascular 
endothelial, inflammatory cells influx, and the activation of portal tract mesenchymal cells 
with fibrogenesis. There is a vicious cycle with lymphocytic obliteration and occlusion of 
the peribiliary plexus and hepatic artery microvasculature, and biliary tract ischemia. These 
alternations give rise to enhance portal tract edema and venous pressure, promote cholesta-
sis as well [41].
2.4.6. The local renin-angiotensin system in liver and insulin resistance
The liver is well known to regulate blood glucose that is why insulin could block glucose 
production on hepatocytes and indirectly decreasing lipolysis in the adipose tissue, and free 
fatty acids. When insulin resistance is developed it enhances gluconeogenesis and lipolysis 
to elevate glucose and free fatty acids in circulation. Therefore, liver tissue plays pivotal role 
in developing insulin resistance [2]. Metabolic syndrome, in other words insulin resistance 
[12], is a complex disease related to obesity, dyslipidemia, hyperglycemia, and hypertension 
as well. Metabolic syndrome is one of the risk factors for developing type-2 diabetes and 
cardiovascular diseases [42]. Therefore, this kind of illness might also be related to insulin 
resistance.
Ang-II involves the development of the insulin resistance [15]. Ang-II declines the insulin-
stimulated tyrosine phosphorylation and thus to block the interaction between phospha-
tidylinositol-3-kinase and insulin receptor substrate (IRS-1) and downregulation insulin 
receptor signal. Hence, Ang-II increases liver glycogenolysis and thus increases gluconeo-
genesis. Taking together, these findings indicated that Ang-II could impair insulin meta-
bolic effects, thus participating in developing insulin resistance. Also, Ang-II led not only 
to decrease lipid storage capacity and triglyceride at adipose tissue but also increase the 
accumulation of triglyceride in liver tissue. These effects might have a well-established piv-
otal contributing to developing insulin resistance as well. So, ACE inhibition is reported to 
improve the insulin sensitivity [43].
The local RAS in the liver might link to improve the insulin resistance related to plasminogen 
activator inhibitor (PAI)-1 in liver tissue. Furthermore, PAI-1 might be activated by TGF-β. 
Takeshita et al. also found that TNF-α increased PAI-1 both mRNA and protein produc-
tions in hepatocytes. They reported of TNF-α could trigger the protein kinase C (PKC), p38 
mitogen-activated protein, kinase/extracellular signal-regulated kinase (ERK), protein tyro-
sine kinase, and NF-κB pathways to induce PAI-1 production in the liver. Ang-II activates 
PKC and NF-κB by 1,2-diacylglycerol production in primary rat hepatocytes. At this moment, 
the local RAS inhibition by AT1 antagonist could abolish TNF-α-induced PAI-1 protein and 
mRNA in liver [14]. The studies are suggested that both classical and alternative RAS path-
ways might involve developing insulin resistance. The classical pathway is ACE-Ang-II-AT1. 
So, one of the previous studies was shown that AT1 inhibition could improve the oral glucose 
test without alteration of the plasma insulin level in diabetic animals. Indeed, Ang-II-AT1 axis 
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probably has a significant role in developing insulin resistance. Therefore, insulin sensitive 
tissue, primarily skeletal muscles could be increased glucose uptake by AT1 inhibition. This 
elevation is, however, thought in partly to relate to the elevated insulin-mediated IRS1-IP3-
GLUT4 axis. On the contrary, it is suggested that angiotensin receptor blocker could increase 
insulin secretion at animals with type-II diabetes. Additionally, it is reported to enhance glu-
cose uptake at adipose tissue, one of the sensitive insulin organs, at AT2-knockdown animals 
[44]. Alternative RAS pathways, ACE2/An-1-7/Mas axis, might be the high beneficial effect on 
diabetes based on enhancing glucose reuptake, diminishing glycogen production, and insulin 
resistance in hepatocytes via Akt/PI3K/IRS-1/JNK insulin signaling. Also, Ang-1-7 declines 
inflammation factors from adipose tissue in obese animal [18].
Giving that there might be a relationship aldosterone and insulin, systemic RAS could, also, 
participate in developing insulin resistance. Because aldosterone could cause insulin resis-
tance based on its hypokalaemia effect on pancreatic beta cells, and also its direct action 
on insulin receptor, elevation gluconeogenesis at the liver, and sodium-glucose cotrans-
porters. The other possible effect of aldosterone is suggested to enhance oxidative stress 
and inflammation in pancreatic beta cells and cause insulin resistance in adipocytes tissue. 
Interestingly, aldosterone is emphasized to affect insulin metabolism in liver, cardiovascu-
lar, renal, adipose, and muscle tissues. Insulin enhances angiotensinogen expression in the 
liver [45].
2.4.7. The local renin-angiotensin system in liver and liver cirrhosis
The role of RAS in liver cirrhosis was shown to enhance intrahepatic pressure via AT1 by 
experimental and human cirrhosis. Ang-II gives rise to contract and proliferates of HSC. There 
has been indicated that an increase of intracellular calcium ion due to the production of ROS, 
release of proinflammatory cytokine and chemokines lead to activate Kupffer cells. These 
cytokines, thus, could destroy hepatocytes and modulate extracellular matrix remodeling. 
Moreover, TGF-β could transform from HSC to myofibroblast, so it plays a crucial effect on 
the development of fibrosis. Kupffer cells are part of the reticuloendothelial system (80–90%) 
and thus are a primary source of cytokines. These cytokines might activate HSC, resulting in 
the production of ECM components, such as TGF-β, fibronectin. Ang-II is reported to develop 
fibrosis by proinflammatory cytokine. Also, Ang-II triggers to the mononuclear cell to synthe-
size more cytokines, especially TGF-β. Moreover, Kupffer cells have shown to express some 
RAS components, including renin, ACE, and AT1 [34].
2.4.8. The local renin-angiotensin system in liver and ischemia/reperfusion injury
Local RAS is reported to play a vital role in I/R injury in the liver. Angiotensinogen, renin, 
and ACE were indicated to involve in I/R injury in the liver. So, ACE inhibition could have 
a positive impact on I/R injury due to liver transplantation. Also, ACE might participate to 
inflammation, fibrosis, and anoxemia of local tissue. ACE2 is newly discovered homology 
of ACE and can transform Ang-II to Ang1-7 which can antagonize Ang-II’s vasocontraction 
effects. When ACE2 is a knockdown, resulting in markedly elevating of Ang-II’s expression 
therefore, it is suggested that ACE2 and ACE can antagonize each other. But this correlation 
between ACE2 and ACE has not been found at liver transplantation yet. It might be due 
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to complication factors interaction of liver transportation, and therefore more studies need 
to evaluate to reveal this complicated interaction in liver pathologies. But, up to now we 
know that ACE2 plays a negative role in RAS. Furthermore, local ACE2 is thought to relate 
to tissue hypoxia as well. In parallel, the expression and activity of local ACE2 are found to 
significantly elevated in the lighting biliary tract in rats and human hepatic cirrhosis and 
other chronic hepatic injuries. The hypoxia is believed to have significant contribution in the 
increase of ACE2 expression, and upregulation of its may participate some protective mech-
anisms against hypoxia conditions. However, healthy liver tissue just is of a trace expres-
sion of ACE and ACE2, but their mRNA and protein expressions have been elevated in the 
transplanted liver of rats. ACE might relate to inflammation due to Ang-II which increases 
the production of TNF, CINC-1, and ICAM-1 in tissue via AT1. So, ACE inhibition reduces 
I/R injury after experimental liver transplantation by the inflammatory promotion process. 
Also, it is reported that renin expression elevated fivefold after reperfusion following the I/R 
model by clamping the portal vein. According to the findings authors concluded that renin 
significantly enhanced at the initial stage of liver transportation, resulting in elevation of 
Ang-I. These elevations lead to increase ACE expression, eventually increasing Ang-II which 
gave rise to diminish blood supply in transplanted liver and aggravates the liver hypoxia, 
combine with inflammation [46].
2.4.9. The local renin-angiotensin system in liver and liver fibrosis
There are many pathologies of liver to cause liver fibrosis, such as alcohol, nonalcoholic fatty 
liver, chronic hepatitis B, and C. Liver fibrosis’s characterization is related to accumulate 
matrix proteins in the tissue, including elastin, collagen, basement glycoproteins, proteogly-
cans, hyaluronan, and finally changing of the matrix composition. Under normal physiologic 
conditions, Disse space in the liver just has proteoglycan, nonfibril forming collagens, such as 
type IV, VI, and XIV and also glycoprotein, i.e., fibronectin, laminin, and tenascin. But, under 
the pathophysiologic conditions, these spaces have some alternation with enhancing fibro-
nectin and tenascin, then the accumulation of Type I, Type III collagen, elastin, and laminin. 
Thereby, liver parenchyma has to be remodeled to accumulate bands of scar tissue. HSC in 
the liver is a perivascular mesenchymal cell, the chiefly fibrogenic cell-type. One of its primary 
functions is retinoid (vitamin A) storages under normal physiologic conditions. However, 
HSC shifts into interstitial myofibroblast which can produce ECM components, profibrotic 
and proinflammatory cytokines and chemokines under the pathophysiologic condition, such 
as liver fibrosis. The activation of HSC can be triggered by responding to paracrine trigger 
from its surrounding cell-like hepatocytes and Kupffer cells as well as alternation of ECM. 
These process can be maintained by some factors and autocrine profibrogenic triggers, i.e., 
TGF-β 1 and platelet-derived growth factor. Nowadays, a well-established pivotal participant 
of both inflammatory cells and activated HSCs is Ang-II [6]. Ang-II can start a proliferation 
of myofibroblast and stellate cells, resulting in initiate inflammatory cell and release some 
profibrotic molecules, i.e., TGF-β, CTGF, and IL-1β. Both human and animal studies reported 
that overexpression of some component of RAS was found at fibrotic liver which is related 
to between Ang-II and TGF-β1 [47]. It suggests that inhibition of hepatic RAS has a beneficial 
effect on suppressing steatosis and fibrosis [12]. Therefore, increasing of Ang-II levels in liver 
tissue is tightly associated with fibrosis [32].
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There is some evidence indicated that both classic and alternative RAS might play a role in 
the development of liver fibrosis. ACE-Ang-II-AT1 axis, classic RAS, is reported to be most 
important for developing liver fibrosis (Figure 3). There is an exciting agreement that the drugs 
of ACE and AT1 inhibitors have been succeeding to heal of liver fibrosis by downregulation of 
some keys cytokines and inflammatory elements. The infusion of Ang-II is reported to cause 
bile duct epithelial cell proliferation, and exacerbation of liver fibrosis in rats with the bile duct 
ligation, resulting in to have the contribution of both local and systemic RAS. Also, Ang-II has 
a potential effect on cell growth and fibrosis which is critical processes of inflammation and 
wound healing as well. This process is activated HCSs by Ang-II though AT1. Moreover, when 
Ang-II incubates with activated HCS, it is shown to enhance intracellular calcium concentration, 
cell contraction, cellular proliferation via mitogen-activated protein kinase pathways. Ang-II in 
human HSCs causes profibrogenic effects on ROS generation via NADPH oxidase. NADPH 
oxidase is also expressed in Kupffer cells, sinusoidal endothelial cells that have to participate in 
developing fibrosis by ROS production as well. Hepatic fibrosis also related to the local RAS’s 
effect on extracellular matrix (ECM) which has a balance between ECM output and degrada-
tion by two enzymes. The name of these two enzymes is matrix metalloproteinases (MMP) and 
tissue inhibitors of metalloproteinases (TIMP), which produce and degrade ECM, respectively. 
The balance equals to 1:1. The Ang-II can run to balance favor of TIMP1 in HSCs via AT1, induc-
tion of protein kinase C. ACE or AT1 inhibitors, therefore, can make a balance again between 
these two enzymes in animal models of fibrosis. The other profibrotic effects of Ang-II depend 
on amplification of inflammatory response, inducing acute-phase reactants, ROS, releasing of 
inflammatory and fibrotic cytokines including IL6, IL1, TGF-β, TNF-α chronic, and ECM depo-
sition in liver injury. It has also induced monocyte chemoattractant protein-1 (MCP-1) and IL-8 
from HCS. MCP-1 triggers leucocytes for fortification and activation. MCP-1 could be upregu-
lated its genes by Rho intracellular pathways via Ang-II and AT1 axis. Ang-II can upregulate 
genes by activator protein-1 (AP-1), signal transducer, and activator of transcription (STAT) 
and NF-κB, which have proinflammatory efficiency, e.g., IL-6. Ang-II and NF-κB are reported 
to have a kind of positive feedback interaction on triggering the transcription of angiotensino-
gen via AT1. Kupffer cells might participate in this proinflammatory effect of Ang-II by AT1. In 
other words, activated Kupffer cells by Ang-II in the alcoholic liver disease generate TGF-β and 
TNF-α. That is why these proinflammatory effects of the Kupffer cell could be declined by AT1 
but not ACE inhibitors. This finding suggested that AT1 in Kupffer cell is a pivotal role in Ang-
II’s inflammatory effect [6]. Human studies of fibrotic treatment are reported to have difficulties 
based on the requirement of taking multiple biopsies from the patient. This brings an enormous 
ethic problem and also makes the patient suffering from pain. This cannot be acceptable for 
anyone. The other difficulties of human studies is related to the illness progression very slow 
in the most disease, e.g.,  hepatitis-C, nonalcoholic liver disease. This slow progression makes it 
difficult to determine of therapeutic beneficial of treatment. It may overcome when the studies 
are planned for tracking patient for many years [6].
Fibrosis is a complicated process including collagen-I accumulation, epithelial to mesenchy-
mal transition (EMT). EMT triggered by TGF-ß1 is a kind of structural and cellular alteration 
leading to separate cells, lose cell polarity, and gain cell adhesion, resulting in facilitating cell 
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motility. Responding to EMT, the extracellular matrix could be exposed to change for allow-
ing cell motility and express some growth factors, e.g., VEGF. Ang-II elevates TGF-ß1 level, 
α-smooth muscle actin and decreases E-cadherin. The fibrosis development after hepatic 
bile duct ligation is reported to participate in both Ang-II and Ang-1-7. According to these 
findings, although Ang-II levels increase in the first week after bile ligation, Ang-1-7 levels 
enhance after 3 weeks of bile ligation. It also emphasized that Ang-II tends to back to its 
normal level after 1 week, but Ang-1-7 maintained its priority after 2 weeks [5]. On the basis 
of these findings, it will be concluded that classical pathways of RAS, ACE-Ang-II-AT1 has 
involved in the development of liver fibrosis more than alternative RAS pathway, ACE2-Ang-
1-7-Mas (Figure 2).
Figure 3. The effect of classical and alternative renin-angiotensin system and the effect on renin angiotensin system 
blockers. The figure was modified from Refs. [6, 18].
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2.4.10. The local renin-angiotensin system in liver and nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is a predominantly chronic hepatic disease in devel-
oped countries, and its prevalence is around 10–24% in the countries. The disease is linked 
to some illness, including obesity, hyperlipidemia, hypertension, type-2 diabetes, and insulin 
resistance (IR) [12], thus hepatic function could be elevated by losing weight [48]. In par-
ticular, there is a significant interaction between NAFLD and IR, also named metabolic syn-
drome that has found approximately 95% NADFLD patient. NADFLD has reported elevating 
inflammation and oxidative stress, leading to release inflammatory cytokines and abnormal 
lipoprotein [12]. Because metabolic syndrome is related to accumulate enormous triglycer-
ides in the tissue, it is shown that ACE antagonist by drugs could help to lose the weight in 
an obese patient [48]. Additionally, according to one of experimental study, the liver was 
indicated to gain weight when fed the high-fat diet for 12 weeks. In contrast, ACE inhibition 
by perindopril was shown to reduce the liver weight and food consume as well. The authors 
suggested that low-food intake might be concerned with Ang-II and corticotropin-releasing 
hormone (CRP), anorexic brain peptide. Ang-II receptors were reported to express at CRP-
containing neurons. Thus, Ang-II is thought to decline CRP expression from the neurons. 
Local Ang-II could cause to release leptin from isolated adipocytes; ACEI could block the 
releasing of leptin. One of the novel results of authors was that ACE activity is high in rat with 
obese-induced by high-fatty acid diet. They thought that elevation of ACE in liver led to accu-
mulate triglyceride. Also, they speculated to associate with elevation ACE and developing 
insulin resistance and type-2 diabetes. They implied when ACE could be pharmacologically 
antagonized; insulin signaling could be modified in the liver, resulting in triggering insulin 
receptor and enhancing glucose uptake by elevation bradykinin based on decline cleavage by 
ACE [48]. Indeed, liver function is also affected by systemic RAS.
Ang-II plays a significant role in the development of liver inflammation and fibrosis. So, when 
Ang-II is blocked by ACE and ACE antagonist drugs, it helps to modify some factors, e.g., 
decreasing cytokine production such as TNF-α, decreasing TGF-β, elevation of adiponectin, 
insulin, and insulin signaling at the cellular level as well as limiting the HSCs activity. HCS in 
the healthy liver has very low concentration of RAS elements, but the cell increases the RAS 
expression, e.g., ACE, AT1 under the pathophysiologic circumstance. After activation of HCS, 
the cell could produce Ang-II which led to trigger some fibrogenic effects, such as cell migra-
tion, proliferation, inflammatory cytokine, and collagen secretions through commonly AT1 
[12]. Ang-II’s fibrogenic effects in the liver, kidney, and also heart are concerned with TGF-β. 
Therefore, RAS inhibition is reported to the therapeutic effect on liver fibrosis and inflamma-
tion based on NAFLD. The oxidative stress levels are reported to relate to NAFLD and also IR 
severity. It is shown to enhance some factors, including TNF-α, TGF-β, plasminogen activa-
tor-1, IL6, and CRP at the patients with NAFLD [12].
Additionally, the liver might be affected by cardiorenal metabolic syndrome (CRS) and type-2 
diabetes mellitus based on metabolic toxicities with the development of the nonalcoholic fatty 
liver disease or steatohepatitis. The liver tissue has occurred some cellular remodeling during 
those pathologies. In the beginning, hepatocytes increase the fat accumulation as a result of 
lipolysis, triglycerides, and free fatty acids. Accumulation of fat triggers oxidative stress and 
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ROS production. Two hypotheses have been proposed to elucidate nonalcoholic fatty liver 
disease progression. The first theory is associated with CRS causing to the development of ste-
atosis. The second approach is associated with hepatocytes injury, inflammation, and fibrosis, 
which causes mostly oxidative stress, elevated cytokines synthesis. The development of fibro-
sis and accumulation of ECM predominantly rely on HCS activity, a sinusoidal pericyte cell. 
HCS led to accumulate type-I and type-III collagen around hepatic sinusoids, probably result-
ing in destroying the structural and function of sinusoidal and endothelial cell-hepatocytes. 
Local RAS in the liver has shown to play a major role in the development of liver fibrosis. That 
is why Ang-II blockage could be attenuate oxidative stress, steatosis, inflammation, and fibro-
sis[2]. Those studies were pointed out the role of systemic RAS in NADFLD. We can speculate 
that there is no available research directly indicated the local RAS in liver. While Ang-II could 
involve a kind of NADFLD, it still needs also to evaluate the role of local RAS in liver.
2.4.11. The local renin-angiotensin system in liver and acute liver failure
Paracetamol is one of the commonly utilized drugs as a painkiller and for decreasing fever 
when it is used at therapeutic doses. It caused hepatotoxicity when it overdoses, a worldwide 
problem, resulting in acute liver failure. The drug’s metabolized process is mainly carried out 
at liver and converted to it nontoxic metabolites which extracted by urine. But, its small pro-
portion usually less than 5% is also metabolized by the cytochrome P450 (CYP) enzyme system 
(generally CYP2E1), and converted to it highly reactive metabolite, named as N-acetyl-p-
benzoquinone imine (NAPQI). Its reactive metabolite leads to a toxic effect through oxidative 
stress. NAPQI covalently binds intracellular proteins based on its reactive electrophilic prop-
erty. Although NAPQI reacts with reduced glutathione (GSH) shifting to nontoxic metabo-
lites at its therapeutic dose, it also reacts with GSH at high doses of paracetamol, but GSH 
could not have enough level of enormous reactive metabolites, resulting from oxidative stress 
and mitochondrial dysfunction. GSH is one of the vital antioxidant enzymes for suppressing 
of the oxidative compound. A decline of GSH could cause mitochondrial oxidative, depress 
mitochondrial respiration, and adenosine triphosphate deprivation, resulting in hepatocytes 
and sinusoidal endothelial cells necrosis. Ang-II is well documented to exaggerate oxidative 
stress. So, Ang-II blocked by aliskiren, renin inhibitors, is reported to decline acute toxicity of 
liver-induced by paracetamol by decreasing oxidative stress. Moreover, aliskiren is shown to 
reduce elevated TGF-α and downregulate activated Kupffer cells and HSCs at the acute liver 
injury induced by paracetamol [49].
3. Conclusion
After recognition of local RAS, the new insight of RAS is shifted to local or tissue due to 
its endocrine function. Systemic RAS may not play important role under pathophysiologic 
conditions but local RAS may play a crucial role under pathophysiologic conditions, espe-
cially independent and/or dependent systemic RAS. The studies have shown that local RAS 
in the liver has a crucial role not only in maintaining the physiologic functions but also in 
 developing pathophysiology. There are limited studies available to evaluate local RAS under 
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a pathophysiologic circumstance. The component of local RAS may present a small amount 
expression in the normal liver tissue. However, its component expressions are increased 
under a pathophysiologic condition, leading to enhance of importance and effects of RAS in 
the tissue. So, some pathophysiologic conditions have been indicated to relate to local RAS, 
such as liver fibrosis, portal hypertension, insulin resistance, liver cirrhosis, cancer growth, 
and metastasis. That is why the new studies are needed to evaluate the local RAS under a 
pathophysiologic condition.
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